Abstract
2/2020
vol. 15
Review paper
Methods for prevention of acute post-endoscopic retrograde cholangiopancreatography pancreatitis
- Department of Internal Medicine and Gastroenterology with IBD Subdivision, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland
- Faculty of Medicine and Health Sciences, Jan Kochanowski University, Kielce, Poland
Gastroenterology Rev 2020; 15 (2): 98–102
Online publish date: 2020/06/08
Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), with incidence rates ranging between 2% and 16%. In addition to being experienced in endoscopic procedures and having knowledge of the patient qualification criteria, physicians should also be aware of the patient and procedure-related risk factors responsible for post-ERCP pancreatitis (PEP). Intrarectal administration of nonsteroidal anti-inflammatory drugs and pancreatic duct stenting were demonstrated to be efficient in high-risk patients. This review provides a broader summary of pharmacological methods and techniques aimed at reducing the risk of PEP.
Keywords
post-endoscopic retrograde cholangiopancreatography pancreatitis, endoscopic retrograde cholangiopancreatography, nonsteroidal anti-inflammatory drugs, pancreatic duct stents
Coverage in
Indexed in
Integrated with
